173 related articles for article (PubMed ID: 33875432)
21. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
Andrei G; Fiten P; Froeyen M; De Clercq E; Opdenakker G; Snoeck R
Antivir Ther; 2007; 12(5):719-32. PubMed ID: 17713155
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet.
Ducancelle A; Gravisse J; Alain S; Fillet AM; Petit F; Pors MJ; Mazeron MC
J Virol Methods; 2005 May; 125(2):145-51. PubMed ID: 15794984
[TBL] [Abstract][Full Text] [Related]
23. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
24. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Chou S
J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
[TBL] [Abstract][Full Text] [Related]
26. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
27. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.
Sauerbrei A; Bohn K; Heim A; Hofmann J; Weissbrich B; Schnitzler P; Hoffmann D; Zell R; Jahn G; Wutzler P; Hamprecht K
Antivir Ther; 2011; 16(8):1297-308. PubMed ID: 22155911
[TBL] [Abstract][Full Text] [Related]
28. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase.
Zahn KE; Tchesnokov EP; Götte M; Doublié S
J Biol Chem; 2011 Jul; 286(28):25246-55. PubMed ID: 21566148
[TBL] [Abstract][Full Text] [Related]
29. Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child.
Stránská R; van Loon AM; Bredius RG; Polman M; Nienhuis E; Beersma MF; Lankester AC; Schuurman R
Antivir Ther; 2004 Feb; 9(1):97-104. PubMed ID: 15040541
[TBL] [Abstract][Full Text] [Related]
30. Herpesvirus DNA polymerases: Structures, functions and inhibitors.
Zarrouk K; Piret J; Boivin G
Virus Res; 2017 Apr; 234():177-192. PubMed ID: 28153606
[TBL] [Abstract][Full Text] [Related]
31. Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance.
Giorgi J; Simon B; Destras G; Semanas Q; Ginevra C; Boyer T; Regue H; Billaud G; Ducastelle S; Ader F; Morfin F; Josset L; Frobert E
Antiviral Res; 2023 Aug; 216():105672. PubMed ID: 37453453
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus.
Sauerbrei A; Deinhardt S; Zell R; Wutzler P
Antiviral Res; 2010 Jun; 86(3):246-52. PubMed ID: 20211650
[TBL] [Abstract][Full Text] [Related]
33. Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.
Kini GD; Beadle JR; Xie H; Aldern KA; Richman DD; Hostetler KY
Antiviral Res; 1997 Sep; 36(1):43-53. PubMed ID: 9330760
[TBL] [Abstract][Full Text] [Related]
34. Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.
Schmidt S; Bohn-Wippert K; Schlattmann P; Zell R; Sauerbrei A
Antimicrob Agents Chemother; 2015 Aug; 59(8):4938-45. PubMed ID: 26055375
[TBL] [Abstract][Full Text] [Related]
35. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
36. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
Martin M; Azzi A; Lin SX; Boivin G
Antivir Ther; 2010; 15(4):579-86. PubMed ID: 20587851
[TBL] [Abstract][Full Text] [Related]
37. UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients.
Labrunie T; Ducastelle S; Domenech C; Ader F; Morfin F; Frobert E
Antiviral Res; 2019 Aug; 168():114-120. PubMed ID: 31152759
[TBL] [Abstract][Full Text] [Related]
38. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.
Gilbert C; Azzi A; Goyette N; Lin SX; Boivin G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4019-27. PubMed ID: 21709106
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid.
Derse D; Bastow KF; Cheng Y
J Biol Chem; 1982 Sep; 257(17):10251-60. PubMed ID: 6286645
[TBL] [Abstract][Full Text] [Related]
40. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
